Regional Treatment Flow and Prognosis ofTraumatic Thoracic Aortic Injuries:A Multi-center Retrospective Analysis in Zhejiang Province During 11 Years
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hanzhou, Zhejiang, China, 310009
- SAHZU
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of trauma patients with aortic dissection (aortic aneurysm) (aortic hematoma)
Exclusion Criteria:
- Patients with primary aortic dissection, limb pseudoaneurysm, non-aortic associated hematoma, etc.Incomplete or lost data, patients refused
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Referral information
first visit to our hospital/transfer from another hospital
|
first visit to our hospital/transfer from another hospital
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Regional Treatment Flow And Prognosis of Traumatic Thoracic Aortic Injuries:A Multi-Center Retrospective Analysis in Zhejiang Province During 11 Years
Time Frame: From January 2010 to October 2020,
|
Numbers of hospitals of different levels
|
From January 2010 to October 2020,
|
|
Regional Treatment Flow And Prognosis of Traumatic Thoracic Aortic Injuries:A Multi-Center Retrospective Analysis in Zhejiang Province During 11 Years
Time Frame: From January 2010 to October 2020,
|
Number of Stanford type(A and B)
|
From January 2010 to October 2020,
|
|
Regional Treatment Flow And Prognosis of Traumatic Thoracic Aortic Injuries:A Multi-Center Retrospective Analysis in Zhejiang Province During 11 Years
Time Frame: From January 2010 to October 2020,
|
survial rate
|
From January 2010 to October 2020,
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2020-859
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.